Jounce Therapeutics, Inc.
JNCE
Price:
$1.88
Market Cap:
$98.95M
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics...[Read more]
Industry
Biotechnology
IPO Date
2017-01-26
Stock Exchange
NASDAQ
Ticker
JNCE
PE Ratio
[-1.96]
ROE
[-25.03%]
Current Ratio
[8.37]
Dividend Yield
[0%]
Enterprise Value
[-41597260.00]
Dividend History
The ROE as of November 2025 (TTM) for Jounce Therapeutics, Inc. (JNCE) is -25.03%
According to Jounce Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -25.03%. This represents a change of 169.43% compared to the average of -9.29% of the last 4 quarters.
Jounce Therapeutics, Inc. (JNCE) Historical ROE (quarterly & annually)
How has JNCE ROE performed in the past?
The mean historical ROE of Jounce Therapeutics, Inc. over the last ten years is 198.91%. The current -25.03% ROE has changed -112.58% with respect to the historical average. Over the past ten years (40 quarters), JNCE's ROE was at its highest in in the September 2019 quarter at 51.65%. The ROE was at its lowest in in the September 2022 quarter at -23.96%.
Average
198.91%
Median
-20.75%
Minimum
-63.61%
Maximum
1.97%
Jounce Therapeutics, Inc. (JNCE) ROE by Quarter and Year
Discovering the peaks and valleys of Jounce Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 167.22%
Maximum Annual ROE = 1.97%
Minimum Annual Increase = -223.78%
Minimum Annual ROE = -63.61%
| Year | ROE | Change |
|---|---|---|
| 2022 | -27.81% | -31.51% |
| 2021 | -40.60% | 95.68% |
| 2020 | -20.75% | -163.75% |
| 2019 | 32.55% | -223.78% |
| 2018 | -26.29% | 167.22% |
| 2017 | -9.84% | -48.39% |
| 2016 | -19.07% | -70.03% |
| 2015 | -63.61% | -103.24% |
Jounce Therapeutics, Inc. (JNCE) Average ROE
How has JNCE ROE performed in the past?
The current ROE of Jounce Therapeutics, Inc. (JNCE) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-29.72%
5-year avg
-16.58%
10-year avg
198.91%
Jounce Therapeutics, Inc. (JNCE) ROE vs. Peers
How is JNCE’s ROE compared to its peers?
Jounce Therapeutics, Inc.’s ROE is greater than HilleVax, Inc. (-44.61%), greater than Aadi Bioscience, Inc. (-8.09%), greater than Miromatrix Medical Inc. (-74.80%), greater than Insight Molecular Diagnostics Inc. (-2898.07%), greater than Cyteir Therapeutics, Inc. (-26.35%), less than Opiant Pharmaceuticals, Inc. (7.31%), greater than RVL Pharmaceuticals plc (-80.88%), greater than Berkeley Lights, Inc. (-55.98%), greater than Tourmaline Bio, Inc. (-30.50%), greater than Decibel Therapeutics, Inc. (-56.38%),
| Company | ROE | Market cap |
|---|---|---|
| -44.61% | $104.76M | |
| -8.09% | $94.89M | |
| -74.80% | $92.95M | |
| -2898.07% | $159.95M | |
| -26.35% | $108.71M | |
| 7.31% | $108.80M | |
| -80.88% | $3.14M | |
| -55.98% | $86.61M | |
| -30.50% | $1.23B | |
| -56.38% | $123.37M |
Build a custom stock screener for Jounce Therapeutics, Inc. (JNCE) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Jounce Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Jounce Therapeutics, Inc. (JNCE) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Jounce Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Jounce Therapeutics, Inc.'s ROE?
How is the ROE calculated for Jounce Therapeutics, Inc. (JNCE)?
What is the highest ROE for Jounce Therapeutics, Inc. (JNCE)?
What is the 3-year average ROE for Jounce Therapeutics, Inc. (JNCE)?
What is the 5-year average ROE for Jounce Therapeutics, Inc. (JNCE)?
How does the current ROE for Jounce Therapeutics, Inc. (JNCE) compare to its historical average?